Targets › MCL1
2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2029.
Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. (UniProt, Q07820)
Open in Phaseline: the race on MCL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ascentage Pharma Group | APG-3288 Dual BCL-2 and MCL-1 inhibitor | BCL2, MCL1, BCL-XL | Phase 1 | Relapsed/Refractory Hematological Malignancies | Dec 2029 |
| Ascentage Pharma Group | APG-1252 BCL-2 family protein inhibitor | BCL2, BCL2L1, BCL2L2, MCL1 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
Relapsed/Refractory Hematological Malignancies (1) EGFR Positive Non-small Cell Lung Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.